Autism Spectrum Disorder Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The autism spectrum disorder market reached a value of USD 1,668.43 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 5,578.38 Million by 2035, exhibiting a growth rate (CAGR) of 11.80% during 2025-2035.

The autism spectrum disorder market has been comprehensively analyzed in IMARC's new report titled "Autism Spectrum Disorder Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Autism spectrum disorder (ASD) refers to a neurodevelopmental condition that affects communication, social interaction, and behavior. It is called a "spectrum" disorder because it can manifest differently in each individual, with varying degrees of severity and symptoms. Some of the common characteristics of the ailment include difficulty with social interactions, communication challenges, repetitive behaviors or routines, sensory sensitivities, etc. Individuals may also have trouble with verbal and nonverbal communication, struggle with maintaining eye contact, and exhibit intense interest in specific topics or objects. Additionally, they may engage in repetitive behaviors like rocking back and forth or hand-flapping and have sensory sensitivities to bright lights or loud noises. Diagnosing ASD typically involves a developmental screening, followed by a diagnostic evaluation that includes detailed assessments of the individual's communication, social interaction, and behavior. These evaluations consist of direct observation, standardized tests, interviews with caregivers and family members, and medical and genetic testing.

The increasing cases of various genetic or chromosomal conditions, such as tuberous sclerosis and fragile X syndrome, are primarily driving the autism spectrum disorder market. Apart from this, the rising prevalence of numerous risk factors that contribute to the onset of the ailment, including abnormal brain development, immune system dysfunction, complications during pregnancy or delivery, etc., is further bolstering the market growth. Moreover, the widespread adoption of several medications, such as antipsychotics, antidepressants, stimulants, etc., for managing some of the symptoms associated with the ailment, like anxiety, depression, hyperactivity, etc., is also creating a positive outlook for the market. Additionally, the escalating demand for applied behavior analysis (ABA) therapy, since it is effective in improving social skills, communication, and behavior in children having ASD, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of sensory integration therapy, which involves exposing individuals with ASD to various sensory experiences, such as touch, sound, and movement, in order to help them better process and integrate sensory information, is expected to drive the autism spectrum disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the autism spectrum disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for autism spectrum disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the autism spectrum disorder market in any manner.

Recent Developments:

• In May 2025, Yamo Pharmaceuticals announced positive Phase 2 results for L1-79, presented at the International Society for Autism Research (INSAR) 2025 Annual Meeting. The 12-week randomized, double-blind, placebo-controlled crossover study revealed statistically significant and clinically meaningful improvements in the Vineland-3 Socialization Standard Score (VSSS) and several secondary outcome measures during the first period, while maintaining a favorable safety profile.
• In June 2024, STALICLA reported the publication of a landmark phase 1b trial study with STP1, a novel combination regimen tailored for the treatment of a clinically and biologically defined subgroup of patients suffering from autism spectrum disorder (ASD), referred to as ASD Phenotype 1 (ASD-Phen1).

Key Highlights:

• Autism spectrum disorder is estimated to affect around one out of every 100 children worldwide.
• Autism spectrum disorder affects around 1.8 million children and adolescents in the United States aged three to seventeen, as well as more than five million adults.
• Studies conducted on many continents (Asia, Europe, and North America) suggest a prevalence rate of roughly 1 to 2 percent.
• Autism spectrum disorder diagnoses remain nearly four times more likely among boys (1 in 34) than girls (1 in 154).
• Approximately 10-15% of autism cases have an identified Mendelian (single gene) disease, chromosome abnormalities, or other genetic syndrome.

Drugs:

STP1 refers to a fixed dose combination of NKCC1 antagonist (bumetanide) and PDE4/3 inhibitor (ibudilast) shown to be a top drug match for a subgroup of patients suffering from autism spectrum disorder called phenotype 1. The PDE inhibitor addresses a chronic inflammatory state associated with the ASD-Phen1 subgroup, while the bumetanide component targets the over-activated NKCC1 to balance neuronal excitation and inhibition.

ML 004 is a selective mGluR5 negative allosteric modulator designed to normalize excitatory glutamatergic signaling. In autism spectrum disorder, dysregulated glutamate activity contributes to impaired synaptic communication and behavioral symptoms. By reducing overactive mGluR5 signaling, ML 004 aims to restore excitatory-inhibitory balance, improving social interaction, cognitive function, and reducing irritability in affected individuals.

RO 7017773 is being developed to treat autism spectrum disorder. The medication candidate is taken orally in the form of tablets or capsules. It works by targeting the GABRA5 receptor. The medication candidate is a novel molecular entity (NME).

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the autism spectrum disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the autism spectrum disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current autism spectrum disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the autism spectrum disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the autism spectrum disorder across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the autism spectrum disorder across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of autism spectrum disorder across the seven major markets?
• What is the number of prevalent cases (2019-2035) of autism spectrum disorder by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of autism spectrum disorder by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with autism spectrum disorder across the seven major markets?
• What is the size of the autism spectrum disorder patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend autism spectrum disorder of?
• What will be the growth rate of patients across the seven major markets?

Autism Spectrum Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for autism spectrum disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the autism spectrum disorder market?
• What are the key regulatory events related to the autism spectrum disorder market?
• What is the structure of clinical trial landscape by status related to the autism spectrum disorder market?
• What is the structure of clinical trial landscape by phase related to the autism spectrum disorder market?
• What is the structure of clinical trial landscape by route of administration related to the autism spectrum disorder market?